6
|
Dinc N, Quick-Weller J, Tritt S, Konczalla J, Mersmann J, Bruder M, Herrmann E, Seifert V, Senft C. Vasospasm of the basilar artery following spontaneous SAH-clinical observations and implications for vascular research. Neurosurg Rev 2018; 42:983-989. [PMID: 30088111 DOI: 10.1007/s10143-018-1015-4] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/02/2018] [Revised: 07/15/2018] [Accepted: 07/19/2018] [Indexed: 10/28/2022]
Abstract
The basilar artery (BA), as a reference vessel for laboratory investigations of cerebral vasospasm (CVS) in many experimental models, warrants a sufficient blood supply despite hemodynamic changes during CVS. In a prospective evaluation study, we analyzed patients who were admitted to our department with subarachnoid hemorrhage (SAH) for the occurrence and sequelae of CVS. Specifically, we sought to identify patients with CVS of the BA. As per institutional protocol, all patients with CVS detected in the posterior circulation had magnetic resonance imaging (MRI) examinations instead of CTA. Between January and December 2016, 74 patients were treated for spontaneous SAH. CVS occurred in 45 (61%) patients, and 31 (42%) patients developed associated cerebral infarctions (CI). CVS was significantly associated with CI (p < 0.0001; OR 44). In 18 (24.3%) patients, CVS significantly affected the basilar artery. Poor admission clinical state, younger age, and treatment modalities were significantly associated with BACVS. BACVS was more often detected in patients with severe CVS (p < 0.046; OR 4.4). Patients with BACVS developed cerebral infarction in a frequency comparable to other patients with CVS (61% vs. 70%, p = 0.7), but none of these infarctions occurred in the brain stem or pons even though vessel diameter was dramatically reduced according to CT- and/or MR-angiography. BACVS does not appear to be followed by cerebral infarction in the BA territory, presumably due to a vascular privilege of this vessel and its perforating branches. In contrast, brain ischemia can frequently be observed in the territories of other major arteries affected by CVS.
Collapse
Affiliation(s)
- Nazife Dinc
- Department of Neurosurgery, Goethe University Hospital Frankfurt, Schleusenweg 2-16, 60528, Frankfurt, Germany.
| | - J Quick-Weller
- Department of Neurosurgery, Goethe University Hospital Frankfurt, Schleusenweg 2-16, 60528, Frankfurt, Germany
| | - S Tritt
- Department of Neuroradiology, Goethe University Hospital, Frankfurt, Germany
| | - J Konczalla
- Department of Neurosurgery, Goethe University Hospital Frankfurt, Schleusenweg 2-16, 60528, Frankfurt, Germany
| | - J Mersmann
- Department of Anesthesiology, Goethe University Hospital, Frankfurt, Germany
| | - M Bruder
- Department of Neurosurgery, Goethe University Hospital Frankfurt, Schleusenweg 2-16, 60528, Frankfurt, Germany
| | - E Herrmann
- Department of Biostatistics and Mathematical Modeling, Goethe University Hospital, Frankfurt, Germany
| | - V Seifert
- Department of Neurosurgery, Goethe University Hospital Frankfurt, Schleusenweg 2-16, 60528, Frankfurt, Germany
| | - C Senft
- Department of Neurosurgery, Goethe University Hospital Frankfurt, Schleusenweg 2-16, 60528, Frankfurt, Germany
| |
Collapse
|
11
|
Westermann D, Mersmann J, Melchior A, Freudenberger T, Petrik C, Schaefer L, Lüllmann-Rauch R, Lettau O, Jacoby C, Schrader J, Brand-Herrmann SM, Young M, Schultheiss H, Levkau B, Baba H, Unger T, Zacharowski K, Tschöpe C, Fischer J. Biglycan Is Required for Adaptive Remodeling After Myocardial Infarction. Circulation 2008; 117:1269-76. [DOI: 10.1161/circulationaha.107.714147] [Citation(s) in RCA: 93] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Background—
After myocardial infarction (MI), extensive remodeling of extracellular matrix contributes to scar formation and preservation of hemodynamic function. On the other hand, adverse and excessive extracellular matrix remodeling leads to fibrosis and impaired function. The present study investigates the role of the small leucine-rich proteoglycan biglycan during cardiac extracellular matrix remodeling and cardiac hemodynamics after MI.
Methods and Results—
Experimental MI was induced in wild-type (WT) and
bgn
−/0
mice by permanent ligation of the left anterior descending coronary artery. Biglycan expression was strongly increased at 3, 7, and 14 days after MI in WT mice.
bgn
−/0
mice showed increased mortality rates after MI as a result of frequent left ventricular (LV) ruptures. Furthermore, tensile strength of the LV derived from
bgn
−/0
mice 21 days after MI was reduced as measured ex vivo. Collagen matrix organization was severely impaired in
bgn
−/0
mice, as shown by birefringence analysis of Sirius red staining and electron microscopy of collagen fibrils. At 21 days after MI, LV hemodynamic parameters were assessed by pressure-volume measurements in vivo to obtain LV end-diastolic pressure, end-diastolic volume, and end-systolic volume.
bgn
−/0
mice were characterized by aggravated LV dilation evidenced by increased LV end-diastolic volume (
bgn
−/0
, 111±4.2 μL versus WT, 96±4.4 μL;
P
<0.05) and LV end-diastolic pressure (
bgn
−/0
, 24±2.7 versus WT, 18±1.8 mm Hg;
P
<0.05) and severely impaired LV function (EF,
bgn
−/0
, 12±2% versus WT, 21±4%;
P
<0.05) 21 days after MI.
Conclusion—
Biglycan is required for stable collagen matrix formation of infarct scars and for preservation of cardiac hemodynamic function.
Collapse
Affiliation(s)
- D. Westermann
- From the Abteilung für Kardiologie und Pneumologie, Charite-Universitätsklinikum Berlin, Campus Benjamin Franklin, Berlin, Germany (D.W., O.L., H.P.S., C.T.); Molecular Cardioprotection and Inflammation Group, Klinik für Anästhesiologie (J.M.) and Molekulare Pharmakologie, Institut für Pharmakologie und Klinische Pharmakologie (A.M., T.F., J.W.F.), Universitätsklinikum Düsseldorf, Düsseldorf, Germany; Center for Cardiovascular Research, Institut für Pharmakologie und Toxikologie, Campus
| | - J. Mersmann
- From the Abteilung für Kardiologie und Pneumologie, Charite-Universitätsklinikum Berlin, Campus Benjamin Franklin, Berlin, Germany (D.W., O.L., H.P.S., C.T.); Molecular Cardioprotection and Inflammation Group, Klinik für Anästhesiologie (J.M.) and Molekulare Pharmakologie, Institut für Pharmakologie und Klinische Pharmakologie (A.M., T.F., J.W.F.), Universitätsklinikum Düsseldorf, Düsseldorf, Germany; Center for Cardiovascular Research, Institut für Pharmakologie und Toxikologie, Campus
| | - A. Melchior
- From the Abteilung für Kardiologie und Pneumologie, Charite-Universitätsklinikum Berlin, Campus Benjamin Franklin, Berlin, Germany (D.W., O.L., H.P.S., C.T.); Molecular Cardioprotection and Inflammation Group, Klinik für Anästhesiologie (J.M.) and Molekulare Pharmakologie, Institut für Pharmakologie und Klinische Pharmakologie (A.M., T.F., J.W.F.), Universitätsklinikum Düsseldorf, Düsseldorf, Germany; Center for Cardiovascular Research, Institut für Pharmakologie und Toxikologie, Campus
| | - T. Freudenberger
- From the Abteilung für Kardiologie und Pneumologie, Charite-Universitätsklinikum Berlin, Campus Benjamin Franklin, Berlin, Germany (D.W., O.L., H.P.S., C.T.); Molecular Cardioprotection and Inflammation Group, Klinik für Anästhesiologie (J.M.) and Molekulare Pharmakologie, Institut für Pharmakologie und Klinische Pharmakologie (A.M., T.F., J.W.F.), Universitätsklinikum Düsseldorf, Düsseldorf, Germany; Center for Cardiovascular Research, Institut für Pharmakologie und Toxikologie, Campus
| | - C. Petrik
- From the Abteilung für Kardiologie und Pneumologie, Charite-Universitätsklinikum Berlin, Campus Benjamin Franklin, Berlin, Germany (D.W., O.L., H.P.S., C.T.); Molecular Cardioprotection and Inflammation Group, Klinik für Anästhesiologie (J.M.) and Molekulare Pharmakologie, Institut für Pharmakologie und Klinische Pharmakologie (A.M., T.F., J.W.F.), Universitätsklinikum Düsseldorf, Düsseldorf, Germany; Center for Cardiovascular Research, Institut für Pharmakologie und Toxikologie, Campus
| | - L. Schaefer
- From the Abteilung für Kardiologie und Pneumologie, Charite-Universitätsklinikum Berlin, Campus Benjamin Franklin, Berlin, Germany (D.W., O.L., H.P.S., C.T.); Molecular Cardioprotection and Inflammation Group, Klinik für Anästhesiologie (J.M.) and Molekulare Pharmakologie, Institut für Pharmakologie und Klinische Pharmakologie (A.M., T.F., J.W.F.), Universitätsklinikum Düsseldorf, Düsseldorf, Germany; Center for Cardiovascular Research, Institut für Pharmakologie und Toxikologie, Campus
| | - R. Lüllmann-Rauch
- From the Abteilung für Kardiologie und Pneumologie, Charite-Universitätsklinikum Berlin, Campus Benjamin Franklin, Berlin, Germany (D.W., O.L., H.P.S., C.T.); Molecular Cardioprotection and Inflammation Group, Klinik für Anästhesiologie (J.M.) and Molekulare Pharmakologie, Institut für Pharmakologie und Klinische Pharmakologie (A.M., T.F., J.W.F.), Universitätsklinikum Düsseldorf, Düsseldorf, Germany; Center for Cardiovascular Research, Institut für Pharmakologie und Toxikologie, Campus
| | - O. Lettau
- From the Abteilung für Kardiologie und Pneumologie, Charite-Universitätsklinikum Berlin, Campus Benjamin Franklin, Berlin, Germany (D.W., O.L., H.P.S., C.T.); Molecular Cardioprotection and Inflammation Group, Klinik für Anästhesiologie (J.M.) and Molekulare Pharmakologie, Institut für Pharmakologie und Klinische Pharmakologie (A.M., T.F., J.W.F.), Universitätsklinikum Düsseldorf, Düsseldorf, Germany; Center for Cardiovascular Research, Institut für Pharmakologie und Toxikologie, Campus
| | - C. Jacoby
- From the Abteilung für Kardiologie und Pneumologie, Charite-Universitätsklinikum Berlin, Campus Benjamin Franklin, Berlin, Germany (D.W., O.L., H.P.S., C.T.); Molecular Cardioprotection and Inflammation Group, Klinik für Anästhesiologie (J.M.) and Molekulare Pharmakologie, Institut für Pharmakologie und Klinische Pharmakologie (A.M., T.F., J.W.F.), Universitätsklinikum Düsseldorf, Düsseldorf, Germany; Center for Cardiovascular Research, Institut für Pharmakologie und Toxikologie, Campus
| | - J. Schrader
- From the Abteilung für Kardiologie und Pneumologie, Charite-Universitätsklinikum Berlin, Campus Benjamin Franklin, Berlin, Germany (D.W., O.L., H.P.S., C.T.); Molecular Cardioprotection and Inflammation Group, Klinik für Anästhesiologie (J.M.) and Molekulare Pharmakologie, Institut für Pharmakologie und Klinische Pharmakologie (A.M., T.F., J.W.F.), Universitätsklinikum Düsseldorf, Düsseldorf, Germany; Center for Cardiovascular Research, Institut für Pharmakologie und Toxikologie, Campus
| | - S.-M. Brand-Herrmann
- From the Abteilung für Kardiologie und Pneumologie, Charite-Universitätsklinikum Berlin, Campus Benjamin Franklin, Berlin, Germany (D.W., O.L., H.P.S., C.T.); Molecular Cardioprotection and Inflammation Group, Klinik für Anästhesiologie (J.M.) and Molekulare Pharmakologie, Institut für Pharmakologie und Klinische Pharmakologie (A.M., T.F., J.W.F.), Universitätsklinikum Düsseldorf, Düsseldorf, Germany; Center for Cardiovascular Research, Institut für Pharmakologie und Toxikologie, Campus
| | - M.F. Young
- From the Abteilung für Kardiologie und Pneumologie, Charite-Universitätsklinikum Berlin, Campus Benjamin Franklin, Berlin, Germany (D.W., O.L., H.P.S., C.T.); Molecular Cardioprotection and Inflammation Group, Klinik für Anästhesiologie (J.M.) and Molekulare Pharmakologie, Institut für Pharmakologie und Klinische Pharmakologie (A.M., T.F., J.W.F.), Universitätsklinikum Düsseldorf, Düsseldorf, Germany; Center for Cardiovascular Research, Institut für Pharmakologie und Toxikologie, Campus
| | - H.P. Schultheiss
- From the Abteilung für Kardiologie und Pneumologie, Charite-Universitätsklinikum Berlin, Campus Benjamin Franklin, Berlin, Germany (D.W., O.L., H.P.S., C.T.); Molecular Cardioprotection and Inflammation Group, Klinik für Anästhesiologie (J.M.) and Molekulare Pharmakologie, Institut für Pharmakologie und Klinische Pharmakologie (A.M., T.F., J.W.F.), Universitätsklinikum Düsseldorf, Düsseldorf, Germany; Center for Cardiovascular Research, Institut für Pharmakologie und Toxikologie, Campus
| | - B. Levkau
- From the Abteilung für Kardiologie und Pneumologie, Charite-Universitätsklinikum Berlin, Campus Benjamin Franklin, Berlin, Germany (D.W., O.L., H.P.S., C.T.); Molecular Cardioprotection and Inflammation Group, Klinik für Anästhesiologie (J.M.) and Molekulare Pharmakologie, Institut für Pharmakologie und Klinische Pharmakologie (A.M., T.F., J.W.F.), Universitätsklinikum Düsseldorf, Düsseldorf, Germany; Center for Cardiovascular Research, Institut für Pharmakologie und Toxikologie, Campus
| | - H.A. Baba
- From the Abteilung für Kardiologie und Pneumologie, Charite-Universitätsklinikum Berlin, Campus Benjamin Franklin, Berlin, Germany (D.W., O.L., H.P.S., C.T.); Molecular Cardioprotection and Inflammation Group, Klinik für Anästhesiologie (J.M.) and Molekulare Pharmakologie, Institut für Pharmakologie und Klinische Pharmakologie (A.M., T.F., J.W.F.), Universitätsklinikum Düsseldorf, Düsseldorf, Germany; Center for Cardiovascular Research, Institut für Pharmakologie und Toxikologie, Campus
| | - T. Unger
- From the Abteilung für Kardiologie und Pneumologie, Charite-Universitätsklinikum Berlin, Campus Benjamin Franklin, Berlin, Germany (D.W., O.L., H.P.S., C.T.); Molecular Cardioprotection and Inflammation Group, Klinik für Anästhesiologie (J.M.) and Molekulare Pharmakologie, Institut für Pharmakologie und Klinische Pharmakologie (A.M., T.F., J.W.F.), Universitätsklinikum Düsseldorf, Düsseldorf, Germany; Center for Cardiovascular Research, Institut für Pharmakologie und Toxikologie, Campus
| | - K. Zacharowski
- From the Abteilung für Kardiologie und Pneumologie, Charite-Universitätsklinikum Berlin, Campus Benjamin Franklin, Berlin, Germany (D.W., O.L., H.P.S., C.T.); Molecular Cardioprotection and Inflammation Group, Klinik für Anästhesiologie (J.M.) and Molekulare Pharmakologie, Institut für Pharmakologie und Klinische Pharmakologie (A.M., T.F., J.W.F.), Universitätsklinikum Düsseldorf, Düsseldorf, Germany; Center for Cardiovascular Research, Institut für Pharmakologie und Toxikologie, Campus
| | - C. Tschöpe
- From the Abteilung für Kardiologie und Pneumologie, Charite-Universitätsklinikum Berlin, Campus Benjamin Franklin, Berlin, Germany (D.W., O.L., H.P.S., C.T.); Molecular Cardioprotection and Inflammation Group, Klinik für Anästhesiologie (J.M.) and Molekulare Pharmakologie, Institut für Pharmakologie und Klinische Pharmakologie (A.M., T.F., J.W.F.), Universitätsklinikum Düsseldorf, Düsseldorf, Germany; Center for Cardiovascular Research, Institut für Pharmakologie und Toxikologie, Campus
| | - J.W. Fischer
- From the Abteilung für Kardiologie und Pneumologie, Charite-Universitätsklinikum Berlin, Campus Benjamin Franklin, Berlin, Germany (D.W., O.L., H.P.S., C.T.); Molecular Cardioprotection and Inflammation Group, Klinik für Anästhesiologie (J.M.) and Molekulare Pharmakologie, Institut für Pharmakologie und Klinische Pharmakologie (A.M., T.F., J.W.F.), Universitätsklinikum Düsseldorf, Düsseldorf, Germany; Center for Cardiovascular Research, Institut für Pharmakologie und Toxikologie, Campus
| |
Collapse
|